Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benlatino: Short Benznidazole Regimens for Chronic Chagas Disease
NCT06339710Phase 3Withdrawn
- Sponsor
- Evandro Chagas Institute
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of benznidazole in Chagas disease (3 arms), sponsored by Evandro Chagas Institute. Primary endpoint: Proportion of participants with sustained negative Polymerase Chain Reaction (PCR) at 24 months. Planned start Jan 2025; status: withdrawn.
02
Drugs
benznidazole
03
Conditions
Chagas disease
Beyond the preview
Go deeper on NCT06339710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06339710.